Specify Company / Ticker to Get the Summary
Dividend History APRE
Dividend Analytics APRE
Max Ratio
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Aprea Therapeutics Inc
APREAprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers; and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania. Address: 3805 Old Easton Road, Doylestown, PA, United States, 18902
Analytics
WallStreet Target Price
13.67 USDP/E Ratio
–Dividend Yield
–Financials APRE
Results | 2019 | Dynamics |